sample pages - vpgcorp.com samplepages.pdfinstruments and five infectious disease tests used for...
TRANSCRIPT
-
MEDICAL DEVICES PHARMACEUTICALS CHEMICALS FOOD & BEVERAGE ELECTRONICS
THE 2014 BLOOD BANKING MARKET: US, EUROPE, JAPANEmerging Opportunities and Business Development Strategies
Sample Pages
Copyright 2014 VENTURE PLANNING GROUP This material is confidential for use by our clients only
and may not be reprinted or reproduced.
VPG Publications, Consulting, Clients www.VPGcorp.com
VPG Market Research Reports www.VPGMarketResearch.com
Partner Reports www.LeadingMarketResearch.com
VENTURE PLANNING GROUP 545 Eighth Avenue, Suite 401 New York, NY 10018 Phone + 1 212 564 2838 Fax + 1 212 564 8133 [email protected]
-
! Clinical Syndromes
The incubation period of West Nile virus is between x and xx days. Most
people who are infected with the West Nile virus either have no symptoms or
experience mild illness, such as fever, headache and body aches before fully
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Encephalitis is the most serioius manifestation of viral infection. Fewer than x%
of people infected with West Nile virus develop encephalitis, and among those
hospitalized with West Nile encephalitis, the case fatality rate changes from x%
to xx%. Therefore, fewer than 1 in 1000 people infected with West Nile virus
die. The elderly, are at increased risk for the development of encephalitis, which
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
polio-loke syndrome has been reported. Genetic factors may influence the
potential for severe encephalitis. Symptoms of encephalitis (inflamation of the
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
! Diagnostic Tests
The FDA has cleared the first test for West Nile virus. The test detects IgM
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
days of the onset of illness. The test was evaluated using over 1,000 patient
samples, which were tested at four different clinical sites. The test identified
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
-
The UVC is well-suited in inactivating non-enveloped viruses that are not
targeted by chemical methods, such as solvent/detergent usage and low pH
techniques. UVC targets the viral DNA and causes the production of photo dimers
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Light energy can also be used to activate a chemical that then can work to
inactivate pathogens. Most of the research in this area has been done pertaining
to psoralens. Psoralens preferentially bind to nucleic acids in the dark, and upon
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
more than six-log inactivation could be achieved with xxxx against HIV, HBV,
HCV, and HCMV viruses. It was further shown by examining bleeding parameters
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
The company is working with another group of compounds called xxxxxx
which require light for viral inactivation. xxxxxx are being developed for viral
inactivation in units of red blood cells. One xxxxxxxxxxxx, has been used to treat
red cells. Early clinical trials of red cells treated with xxxxx have shown that S-
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxx
-
xx xxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxx
7. Grifols Diana
The Diana user gel cards, which consists of plastic support of eight
micro tubes. The tubes contain a gel in a buffered solution with particle sizes to
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
vessel after centrifugation. The micro tubes consist of a reaction chamber and a
column. The sensitising and agglutination reactions takes place in the reaction
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
identification and cross matches). In direct tests, such as cell group typing and
direct Coombs, the chamber is the place where samples are dispensed. The
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
the micro tube. The gel is mixed with reagents for direct typing or polyvalent anti-
human globulin for the Coombs test. All reagents for direct tests are monoclonal.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
-
instruments and five infectious disease tests used for screening donated blood to
the xx members of the American Blood Centers.
The company's traditional marketing strategy for selling diagnostic products
is to place the instruments free of charge in return for the reagent contract. This
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
successful for marketing Hepatitis and AIDS tests.
Outside the U.S., Abbott is present in over xxx countries, including all major
European markets, Japan Canada and Australia. The company is also very active
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
through approximately xxx field representatives and the local country distributing
agents.
In addition to extending its portfolio of immunodiagnostic blood screening
tests, the company is also developing molecular diagnostic assays for blood and
plasma screening. xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
target cycling background reduction process based on magnetic separation
hardware system. xxxxx has developed the HIV nucleic acid probe-based assay
designed to determine the quantity of AIDS virus RNA in the blood. The assay
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
Philadelphia. The detection sensitivity of the test is approximately xx infected
cells per cubic centimeter of blood. xxxxx has also obtained a non-exclusive
license to xxxxxx four patents (including the patent for sandwich hybridization
technology) in order to simplify the company's xxxxxxx replicase amplification
-
acute rheumatoid arthritis and some individuals will have detectable rheumatoid
factor transiently. It is not clear whether B19 arthropathy is due to autoimmune
mechanisms or direct viral infection. B19 nucleic acid has been found in the
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
? Transient Aplastic Crisis
Parvovirus B19 can cause a severe erythropoietic arrest in patients
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
spherocytosis, thalassemia, hemoglobin SC, and other chronic hemolytic states.
The virus can also cause red blood cell aplastic crisis in healthy individuals who do
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
profound fatigue and lethargy, dyspnea, and may or may not have a history of a
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
with absent reticulocytes. Urgent transfusion may be necessary. Examination of
the bone marrow shows erythroid hypoplasia with other cell lines usually intact.
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
pathognomonic for this infection. B19 viremia has been demonstrated during this
time, and patients are potentially still infectious. The aplastic crisis usually
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
? Transient Pancytopenia
Other cells besides the erytrocytes can be involved with an acute
parvovirus B19 infection. Potentially life-threatening declines in the neutrophil
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
-
TABLE III-14
FRANCEALL MARKET SEGMENTS
BLOOD TYPING AND GROUPING REAGENT MARKET2012-2017($ millions)
Annual Growth 2012-2017
Test 2012 2017 (%)
Hospitals
Blood Banks
Commercial/Private Laboratories
Total
-
TABLE IV-11
GERMANYBLOOD BANKS
INFECTIOUS DISEASE SCREENING TEST VOLUME2012-2017
(millions of tests)
Annual Growth 2012-2017
Test 2012 2017 (%)
AIDS HIV NAT HIV-1/2CytomegalovirusHepatitis HAV NAT HBV NAT HBs Ag HCV NAT HCV ALT/SGPTParvovirus B19 NATSyphilis
Total
-
TABLE IX-10
U.S.A.COMMUNITY AND REGIONAL BLOOD CENTERSBLOOD TYPING AND GROUPING TEST VOLUME
2012-2017(millions of tests)
Annual Growth 2012-2017
Test 2012 2017 (%)
ABOAntibody PanelsAntibody Screening/Indirect AntiglobulinAntigen Typing C c Duffy E e I, i Kell Kidd Le a, b MN P S sAntiglobulin Direct C3 + IgG IgG C3Crossmatching Immediate Spin Full CrossmatchRh D DuOthers
Total
-
TABLE IX-17
U.S.A.PLASMA FRACTIONATION CENTERS
INFECTIOUS DISEASE SCREENING TEST VOLUME2012-2017
(millions of tests)
Annual Growth 2012-2017
Test 2012 2017 (%)
AIDS HIV NAT HIV-1/2CytomegalovirusHepatitis HAV NAT HBV NAT HBs Ag Anti-HBc HCV NAT HCV ALT/SGPTHTLV-I/IIParvovirus B19 NATSyphilisWest Nile Virus NAT
Total
-
TABLE IX-23
U.S.A.COMMUNITY AND REGIONAL BLOOD CENTERS
BLOOD TYPING AND GROUPING REAGENT MARKET BY MAJOR TEST2012-2017($ millions)
Annual Growth 2012-2017
Test 2012 2017 (%)
ABOAntibody PanelsAntibody Screening/Indirect AntiglobulinAntigen TypingAntiglobulin Direct OthersCrossmatchingRhOthers
Total
-
TABLE IX-33
U.S.A.MAJOR SUPPLIERS OF BLOOD TYPING AND GROUPING REAGENTS
ESTIMATED SALES AND MARKET SHARES2012
Sales Market ShareSupplier ($ millions) (%)
Total
-
TABLE IX-35
U.S.A.HEPATITIS B BLOOD SCREENING MARKET
REAGENT SALES BY MAJOR SUPPLIER2012
Sales Market ShareSupplier ($ millions) (%)
Total
-
TABLE IX-38
U.S.A.WEST NILE VIRUS NAT MARKET
REAGENT SALES BY MAJOR SUPPLIER2012
Sales Market ShareSupplier ($ millions)(*) (%)
Total
(*) Includes community and reagent blood centers.